Abstract: The present invention relates to pyrazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).
Type:
Grant
Filed:
June 24, 2014
Date of Patent:
September 25, 2018
Assignee:
Merck Patent GmbH
Inventors:
Henry Yu, Marianne Donnelly, Ngan Nguyen, Xuliang Jiang
Abstract: The present invention relates to liquid-crystalline media comprising a) one or more compounds of the formula ST-1, as defined herein, and b) one or more compounds of the formula ST-2, as defined herein, and c) one or more compounds of the formula RV, as defined herein, and d) one or more compounds selected from formula IA and IB, as defined herein, and to liquid-crystal displays containing these media, especially to displays addressed by an active matrix and in particular to displays of the in-plane switching (IPS) or fringe-field switching (FFS) type.
Abstract: The invention relates to arylamino compounds and to the use thereof in electronic devices, for example organic electroluminescent devices. The invention furthermore relates to electronic devices comprising one or more of the said compounds, for example as hole-transport materials in a corresponding functional layer of the device. The invention furthermore relates to a process for the preparation of the said compounds, and to a formulation comprising one or more of the said compounds.
Type:
Application
Filed:
May 23, 2018
Publication date:
September 20, 2018
Applicant:
Merck Patent GmbH
Inventors:
Philipp Stoessel, Frank Voges, Arne Buesing, Christof Pflumm, Teresa Mujica-Fernaud, Christian Wirges
Abstract: Liquid-crystalline media containing a) one or more compounds of formula IA, and b) one or more compounds of formula II and c) one or more compounds of formulae III-1 to III-4, their use in electro-optical displays, particularly in active-matrix displays based on the VA, ECB, FFS or IPS effect.
Abstract: A liquid-crystalline medium which comprises at least one compound of the formula I, and one or more compounds of the formula ST and to the use thereof for an active-matrix display, in particular based on the VA, PSA, PA-VA, SS-VA, SA-VA, PS-VA, PALC, IPS, PS-IPS, UB-FFS, U-IPS, FFS or PS-FFS effect.
Abstract: Disclosed are pigment powders containing only coated BiOCl flakes, which flakes area) BiOCl flakes having a coating containing yellow iron oxide Fe2O3*xH2O, optionally a colorant, optionally an adjuvant, and optionally SiO2, b) BiOCl flakes having a coating containing SiO2, optionally a colorant, and optionally an adjuvant, c) BiOCl flakes having a coating containing a colorant, SiO2, optionally yellow iron oxide Fe2O3*xH2O, and optionally an adjuvant, or d) BiOCl flakes having a coating containing Fe3O4 and optionally SiO2, to a process for the preparation of the pigment powders, and to the use thereof especially in cosmetic formulations.
Type:
Application
Filed:
March 19, 2018
Publication date:
September 20, 2018
Applicant:
Merck Patent GmbH
Inventors:
Padma KAVIRATNA, Mark TELLEFSEN, Qingmin CHENG, Matthew EDDENS, Qinyun PENG
Abstract: The invention relates to arylamino compounds and to the use thereof in electronic devices, for example organic electroluminescent devices. The invention furthermore relates to electronic devices comprising one or more of the said compounds, for example as hole-transport materials in a corresponding functional layer of the device. The invention furthermore relates to a process for the preparation of the said compounds, and to a formulation comprising one or more of the said compounds.
Type:
Application
Filed:
May 23, 2018
Publication date:
September 20, 2018
Applicant:
Merck Patent GmbH
Inventors:
Philipp Stoessel, Frank Voges, Arne Buesing, Christof Pflumm, Teresa Mujica-Fernaud, Christian Wirges
Abstract: The present invention relates to compounds of the formula (I) and in particular to medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries arthritis, pain, allodynia or hyperalgesia.
Abstract: The present invention relates to liquid-crystalline media (LC media) comprising a low-molecular-weight component, a self-alignment additive comprising a thiol group and optionally a polymerizable component. The self-alignment additives effect homeotropic (vertical) alignment of the LC media at a surface or the cell walls of a liquid-crystal display (LC display). The invention therefore also encompasses LC displays having homeotropic alignment of the liquid-crystalline medium (LC medium) without alignment layers. The invention discloses novel structures for self-alignment additives which have a thiol functional groups.
Abstract: The present invention relates to coated zinc sulfide pigments and to the use thereof, preferably in paints, automotive paints, industrial coatings, powder coatings, plastics, printing inks, ceramic glazes and cosmetic formulations, and to a process for the preparation thereof.
Type:
Application
Filed:
July 29, 2016
Publication date:
September 13, 2018
Applicant:
MERCK PATENT GMBH
Inventors:
Helge Bettina KNIESS, Ulrich QUITTMANN, Oliver Robert PIENING
Abstract: The present invention relates compositions comprising an organic semiconducting material, a solvent, and specifically selected polymer particles, which allow modifying the viscosity of such compositions. The present application further relates to the use of such compositions in the production of organic electronic devices.
Abstract: The present invention relates to the compounds of the formula (1) and to organic electroluminescent devices, in particular blue-emitting devices, in which these compounds are used as host material or dopant in the emitting layer and/or as hole-transport material and/or as electron-transport material.
Abstract: The invention relates to a liquid-crystalline medium, having particular dielectric properties, in that it has: either a dielectric constant perpendicular to the director (??) in the range of 2 or more to less 8 or less and at the same time a ratio of the dielectric constant perpendicular to the director (??) to the dielectric anisotropy (??), i.e. (??/??) of 1.0 or more or or a dielectric constant perpendicular to the director (??) of 8 or more and a dielectric anisotropy (??) of 26 or less and preferably comprises one or more compounds having a high dielectric constant perpendicular to the director (??) and a high average dielectric constant (?av.). These compounds are suitable for use in an electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect.
Abstract: Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.
Type:
Grant
Filed:
February 12, 2015
Date of Patent:
September 11, 2018
Assignee:
Merck Patent GmbH
Inventors:
Michael Super, Jonathan Davis, Pascal Andre Stein
Abstract: The present invention relates to compounds of the formula (1), to the use thereof in electronic devices, and to electronic devices, particularly organic electroluminescence devices, comprising said compounds according to the invention, particularly as blue emitting material in an emitting layer.
Type:
Grant
Filed:
April 21, 2015
Date of Patent:
September 11, 2018
Assignee:
Merck Patent GmbH
Inventors:
Arne Buesing, Holger Heil, Philipp Stoessel
Abstract: The invention relates to liquid-crystalline media which can be used, in particular, for electro-optical displays having active-matrix addressing based on the ECB effect and for IPS (in-plane switching) displays or FFS (fringe field switching) displays.
Type:
Grant
Filed:
December 20, 2012
Date of Patent:
September 11, 2018
Assignee:
Merck Patent GmbH
Inventors:
Melanie Klasen-Memmer, Marcus Reuter, Rocco Fortte, Detlef Pauluth, Matthias Bremer, Helmut Haensel, Harald Hirschmann
Abstract: The present invention relates to the use of at least one cyclohexanol derivative of the formula (I) and/or (II) as antimicrobial active compound or as anti-acne, antidandruff, antiperspirant or deodorant active compound, to preparations comprising these compounds, and to specific cyclohexanol derivatives and to a process for the preparation thereof.
Abstract: The present invention relates to formulations having extended release of active ingredient, comprising an active ingredient from BCS Class I having high solubility and high permeability in a polyvinyl alcohol-containing matrix, from which the active ingredient is released at a controlled rate over a therapeutically relevant time period independently of the composition of the release medium.
Abstract: The present invention provides methods of preparing Praziquantel, in particular (R)-Praziquantel and analogues thereof in a stereoselective manner. One method involves asymmetric hydrogenation of the following intermediate compound and subsequent cyclization.
Type:
Application
Filed:
August 10, 2016
Publication date:
September 6, 2018
Applicant:
Merck Patent GmbH
Inventors:
Luc EBERHARDT, Andreas WAECHTLER, David MAILLARD, Stefan LEHMANN